Want to create interactive content? It’s easy in Genially!
atala.martin
Created on January 30, 2023
Discover more than 1500 professional designs like these:
Explore all templates
Lurbinectedina ya es el tratamiento de mayor elección en 2L SCLC
% de participación de mercado en 2L SCLC en EE. UU.
pharma mar cas 02
atala.martin
Created on January 30, 2023
Start designing with a free template
Discover more than 1500 professional designs like these:
View
Practical Interactive Image
View
Akihabara Square Interactive Image
View
Akihabara Interactive Image
View
Essential Interactive Image
View
Interactive Team Image
View
Image with Audio
View
Image with interactive hotspots
Explore all templates
Transcript
Lurbinectedina ya es el tratamiento de mayor elección en 2L SCLC
% de participación de mercado en 2L SCLC en EE. UU.
37%